person · Reporting owner
Slootweg Hugo Alexander
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Forbion European Acquisition Corp.FRBNU · Entity 108709 | Director | December 09, 2021 | December 09, 2021 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director | December 29, 2023 | December 29, 2023 |
| Replimune Group, Inc.REPL · Entity 4707 | Director | April 01, 2023 | April 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Forbion European Acquisition Corp.
Report date December 09, 2021 · Filed December 09, 2021
This filing explicitly reported no securities owned.
NewAmsterdam Pharma Co N.V.
Report date December 29, 2023 · Filed December 29, 2023
This filing explicitly reported no securities owned.
Replimune Group, Inc.
Report date April 01, 2023 · Filed April 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.66 · Expires 2033-04-01 | Direct | 25,200 |
Reported balance
After 2023-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-01 · Grant · Acquired 25,200 · Balance 25,200 F1: The shares underlying this option vest entirely on April 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest entirely on April 1, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2023 Filed Apr 5, 2023 00:04 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 25,200 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041736 · tm2311410-15_4seq1.xml · derivative · entry 1 Slootweg Hugo Alexander · CIK 0001744922 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,200 Underlying: Common Stock · 25,200 shares Expires 2033-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2024. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:10 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001104659-22-042752 · tm2211665-12_4seq1.xml · derivative · entry 1 Slootweg Hugo Alexander · CIK 0001744922 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2023. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:12 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046721 · tm2112099-3_4seq1.xml · derivative · entry 1 Slootweg Hugo Alexander · CIK 0001744922 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2022. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 20:33 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001104659-20-042507 · a4.xml · derivative · entry 1 Slootweg Hugo Alexander · CIK 0001744922 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2030-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2021. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:44 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001104659-19-019727 · a4.xml · derivative · entry 1 Slootweg Hugo Alexander · CIK 0001744922 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2029-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2020. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:26 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047460 · a4.xml · derivative · entry 10 Slootweg Hugo Alexander · CIK 0001744922 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2028-07-19 F5 · derivative.exercise_date: This option was granted on July 19, 2018 subject to the completion of the Issuer's initial public offering, which closed on July 24, 2018. 25% of the shares underlying this stock option vest on July 19, 2019 and the remainder of the shares underlying this stock option vest in 24 equal monthly installments thereafter. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:26 UTC | Replimune Group, Inc. REPL · Entity 4707 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,013,547 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047460 · a4.xml · derivative · entry 9 Slootweg Hugo Alexander · CIK 0001744922 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,013,547 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the completion of the Issuer's initial public offering, each share of the Issuer's series seed convertible preferred stock, series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F4 · shares: Reflects the number of shares of the applicable series of preferred stock held by the Reporting Person on an as-converted to common stock basis. F1 · derivative.exercise_date: In connection with the completion of the Issuer's initial public offering, each share of the Issuer's series seed convertible preferred stock, series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: In connection with the completion of the Issuer's initial public offering, each share of the Issuer's series seed convertible preferred stock, series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F4 · derivative.underlying_shares: Reflects the number of shares of the applicable series of preferred stock held by the Reporting Person on an as-converted to common stock basis. F2 · ownership.nature: The securities are held directly by Forbion Capital Fund III Cooperatief U.A ("Forbion Coop"). Forbion III Management B.V. ("Forbion Management") is the director of Forbion Coop. The Reporting Person serves as one of the directors of Forbion Management and disclaims beneficial ownership over all shares of the Issuer for which Forbion Management may be deemed to beneficially own, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:26 UTC | Replimune Group, Inc. REPL · Entity 4707 | ConversionSeries A Convertible Preferred Stock · Derivative | 2,579,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047460 · a4.xml · derivative · entry 8 Slootweg Hugo Alexander · CIK 0001744922 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,579,881 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the completion of the Issuer's initial public offering, each share of the Issuer's series seed convertible preferred stock, series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F4 · shares: Reflects the number of shares of the applicable series of preferred stock held by the Reporting Person on an as-converted to common stock basis. F1 · derivative.exercise_date: In connection with the completion of the Issuer's initial public offering, each share of the Issuer's series seed convertible preferred stock, series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: In connection with the completion of the Issuer's initial public offering, each share of the Issuer's series seed convertible preferred stock, series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F4 · derivative.underlying_shares: Reflects the number of shares of the applicable series of preferred stock held by the Reporting Person on an as-converted to common stock basis. F2 · ownership.nature: The securities are held directly by Forbion Capital Fund III Cooperatief U.A ("Forbion Coop"). Forbion III Management B.V. ("Forbion Management") is the director of Forbion Coop. The Reporting Person serves as one of the directors of Forbion Management and disclaims beneficial ownership over all shares of the Issuer for which Forbion Management may be deemed to beneficially own, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:26 UTC | Replimune Group, Inc. REPL · Entity 4707 | ConversionSeries Seed Convertible Preferred Stock · Derivative | 994,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047460 · a4.xml · derivative · entry 7 Slootweg Hugo Alexander · CIK 0001744922 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 994,688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the completion of the Issuer's initial public offering, each share of the Issuer's series seed convertible preferred stock, series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F4 · shares: Reflects the number of shares of the applicable series of preferred stock held by the Reporting Person on an as-converted to common stock basis. F1 · derivative.exercise_date: In connection with the completion of the Issuer's initial public offering, each share of the Issuer's series seed convertible preferred stock, series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: In connection with the completion of the Issuer's initial public offering, each share of the Issuer's series seed convertible preferred stock, series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F4 · derivative.underlying_shares: Reflects the number of shares of the applicable series of preferred stock held by the Reporting Person on an as-converted to common stock basis. F2 · ownership.nature: The securities are held directly by Forbion Capital Fund III Cooperatief U.A ("Forbion Coop"). Forbion III Management B.V. ("Forbion Management") is the director of Forbion Coop. The Reporting Person serves as one of the directors of Forbion Management and disclaims beneficial ownership over all shares of the Issuer for which Forbion Management may be deemed to beneficially own, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:26 UTC | Replimune Group, Inc. REPL · Entity 4707 | ConversionWarrant (right to buy) · Derivative | 248,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047460 · a4.xml · derivative · entry 6 Slootweg Hugo Alexander · CIK 0001744922 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Series Seed Convertible Preferred Stock · 248,672 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Reflects warrants to acquire shares of the Issuer's Series Seed Convertible Preferred Stock which automatically converted into warrants to acquire shares of the Issuer's common stock immediately prior to the completion of the Issuer's initial public offering on a 1-for-9.94688 basis without payment or consideration. The warrants have no expiration date. The exercise price is $1.01 per share of the issuer's common stock. F4 · shares: Reflects the number of shares of the applicable series of preferred stock held by the Reporting Person on an as-converted to common stock basis. F3 · derivative.exercise_date: Reflects warrants to acquire shares of the Issuer's Series Seed Convertible Preferred Stock which automatically converted into warrants to acquire shares of the Issuer's common stock immediately prior to the completion of the Issuer's initial public offering on a 1-for-9.94688 basis without payment or consideration. The warrants have no expiration date. The exercise price is $1.01 per share of the issuer's common stock. F3 · derivative.expiration_date: Reflects warrants to acquire shares of the Issuer's Series Seed Convertible Preferred Stock which automatically converted into warrants to acquire shares of the Issuer's common stock immediately prior to the completion of the Issuer's initial public offering on a 1-for-9.94688 basis without payment or consideration. The warrants have no expiration date. The exercise price is $1.01 per share of the issuer's common stock. F4 · derivative.underlying_shares: Reflects the number of shares of the applicable series of preferred stock held by the Reporting Person on an as-converted to common stock basis. F2 · ownership.nature: The securities are held directly by Forbion Capital Fund III Cooperatief U.A ("Forbion Coop"). Forbion III Management B.V. ("Forbion Management") is the director of Forbion Coop. The Reporting Person serves as one of the directors of Forbion Management and disclaims beneficial ownership over all shares of the Issuer for which Forbion Management may be deemed to beneficially own, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:26 UTC | Replimune Group, Inc. REPL · Entity 4707 | ConversionWarrant (right to buy) · Derivative | 248,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047460 · a4.xml · derivative · entry 5 Slootweg Hugo Alexander · CIK 0001744922 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 248,672 Underlying: Common Stock · 248,672 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Reflects warrants to acquire shares of the Issuer's Series Seed Convertible Preferred Stock which automatically converted into warrants to acquire shares of the Issuer's common stock immediately prior to the completion of the Issuer's initial public offering on a 1-for-9.94688 basis without payment or consideration. The warrants have no expiration date. The exercise price is $1.01 per share of the issuer's common stock. F4 · shares: Reflects the number of shares of the applicable series of preferred stock held by the Reporting Person on an as-converted to common stock basis. F3 · derivative.exercise_date: Reflects warrants to acquire shares of the Issuer's Series Seed Convertible Preferred Stock which automatically converted into warrants to acquire shares of the Issuer's common stock immediately prior to the completion of the Issuer's initial public offering on a 1-for-9.94688 basis without payment or consideration. The warrants have no expiration date. The exercise price is $1.01 per share of the issuer's common stock. F3 · derivative.expiration_date: Reflects warrants to acquire shares of the Issuer's Series Seed Convertible Preferred Stock which automatically converted into warrants to acquire shares of the Issuer's common stock immediately prior to the completion of the Issuer's initial public offering on a 1-for-9.94688 basis without payment or consideration. The warrants have no expiration date. The exercise price is $1.01 per share of the issuer's common stock. F4 · derivative.underlying_shares: Reflects the number of shares of the applicable series of preferred stock held by the Reporting Person on an as-converted to common stock basis. F4 · balance_after: Reflects the number of shares of the applicable series of preferred stock held by the Reporting Person on an as-converted to common stock basis. F2 · ownership.nature: The securities are held directly by Forbion Capital Fund III Cooperatief U.A ("Forbion Coop"). Forbion III Management B.V. ("Forbion Management") is the director of Forbion Coop. The Reporting Person serves as one of the directors of Forbion Management and disclaims beneficial ownership over all shares of the Issuer for which Forbion Management may be deemed to beneficially own, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:26 UTC | Replimune Group, Inc. REPL · Entity 4707 | PurchaseCommon Stock | 133,333 | $15.00 | $1,999,995.00 |
DisclosureSEC source: 0001104659-18-047460 · a4.xml · nonDerivative · entry 4 Slootweg Hugo Alexander · CIK 0001744922 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,721,449 F2 · ownership.nature: The securities are held directly by Forbion Capital Fund III Cooperatief U.A ("Forbion Coop"). Forbion III Management B.V. ("Forbion Management") is the director of Forbion Coop. The Reporting Person serves as one of the directors of Forbion Management and disclaims beneficial ownership over all shares of the Issuer for which Forbion Management may be deemed to beneficially own, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:26 UTC | Replimune Group, Inc. REPL · Entity 4707 | ConversionCommon Stock | 1,013,547 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-047460 · a4.xml · nonDerivative · entry 3 Slootweg Hugo Alexander · CIK 0001744922 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,588,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the completion of the Issuer's initial public offering, each share of the Issuer's series seed convertible preferred stock, series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held directly by Forbion Capital Fund III Cooperatief U.A ("Forbion Coop"). Forbion III Management B.V. ("Forbion Management") is the director of Forbion Coop. The Reporting Person serves as one of the directors of Forbion Management and disclaims beneficial ownership over all shares of the Issuer for which Forbion Management may be deemed to beneficially own, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:26 UTC | Replimune Group, Inc. REPL · Entity 4707 | ConversionCommon Stock | 2,579,881 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-047460 · a4.xml · nonDerivative · entry 2 Slootweg Hugo Alexander · CIK 0001744922 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,574,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the completion of the Issuer's initial public offering, each share of the Issuer's series seed convertible preferred stock, series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held directly by Forbion Capital Fund III Cooperatief U.A ("Forbion Coop"). Forbion III Management B.V. ("Forbion Management") is the director of Forbion Coop. The Reporting Person serves as one of the directors of Forbion Management and disclaims beneficial ownership over all shares of the Issuer for which Forbion Management may be deemed to beneficially own, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:26 UTC | Replimune Group, Inc. REPL · Entity 4707 | ConversionCommon Stock | 994,688 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-047460 · a4.xml · nonDerivative · entry 1 Slootweg Hugo Alexander · CIK 0001744922 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 994,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the completion of the Issuer's initial public offering, each share of the Issuer's series seed convertible preferred stock, series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held directly by Forbion Capital Fund III Cooperatief U.A ("Forbion Coop"). Forbion III Management B.V. ("Forbion Management") is the director of Forbion Coop. The Reporting Person serves as one of the directors of Forbion Management and disclaims beneficial ownership over all shares of the Issuer for which Forbion Management may be deemed to beneficially own, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.